SEC Form 4 · accession 0001127602-15-003076
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairman & Co-CEO · Director
Period of report
Jan 28, 2015
Accepted (ET)
Jan 28, 2015 · 5:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 28, 2015 | M | 2,211 | $63.22 | A | 2,351 | D | |
| Common StockF2 | Jan 28, 2015 | S | 401 | $144.1723 | D | 1,950 | D | |
| Common StockF3 | Jan 28, 2015 | S | 1,510 | $145.5007 | D | 440 | D | |
| Common Stock | Jan 28, 2015 | S | 100 | $146.18 | D | 340 | D | |
| Common Stock | Jan 28, 2015 | S | 100 | $147.00 | D | 240 | D | |
| Common Stock | Jan 28, 2015 | S | 100 | $148.47 | D | 140 | D | |
| Common Stock | holding | — | — | — | 166 | I | By Spouse | |
| Common Stock | holding | — | — | — | 533,094 | I | By Trusts |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $63.22 | Jan 28, 2015 | M | 2,211 | D | Dec 31, 2010 | Dec 31, 2020 | Common Stock | 2,211 | 451,063 | D |
Explanation of responses
- F1This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
- F2This transaction was executed in multiple trades at prices ranging from $143.94 to $144.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $145.04 to $146.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.